Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742963 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
A Phase 1 study, sponsored by ImmunoGenesis.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT00742963 is a Phase 1 study that has completed, run by ImmunoGenesis. The registered enrollment target is 107 participants.
The verdict
NCT00742963, a Phase 1 study, has completed, sponsored by ImmunoGenesis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.
Interventions
- DRUG TH-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742963
The ClinicalTrials.gov registry entry for NCT00742963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGenesis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TH-302 is the first listed.
NCT00742963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00742963 about?
NCT00742963 is a clinical study titled "Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma". The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.
What is the current status of trial NCT00742963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2008-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00742963?
The interventions under investigation include: TH-302 (DRUG).
Who is sponsoring clinical trial NCT00742963?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.